
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Source:</strong> American College of Gastroenterology, <em>Am J Gastroenterol</em> 2025;120:31‑59  </li>
<li style="margin-left: 0px;"><strong>Authors:</strong> Evan S. Dellon MD, MPH, FACG et al.</li>
</ul>
<details><summary><strong>1. Overview &amp; Epidemiology  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Chronic immune‑mediated esophageal disease → symptoms + ≥15 eos/hpf.  </li>
<li style="margin-left: 0px;">Incidence &amp; prevalence ↑ rapidly (global meta‑analysis 2023).  </li>
<li style="margin-left: 0px;">Affects GI, allergy, ED, primary‑care settings; common cause of food impaction.  </li>
<li style="margin-left: 0px;">Diagnostic delay → “tip of the iceberg” of undetected cases.  </li>
</ul>
<details><summary><strong>1.1 Historical Shift  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">2013 guideline required PPI trial → now eliminated (PPI‑REE no longer a diagnostic criterion).  </li>
<li style="margin-left: 0px;">New consensus (AGREE, 2018) defines EoE without PPI response requirement.  </li>
</ul>
</div></details>
<details><summary><strong>1.2 Risk Factors &amp; Comorbidities  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Atopic diseases (asthma, eczema, allergic rhinitis) present in 60‑80% of patients.  </li>
<li style="margin-left: 0px;">Family history ↑ risk; clustering observed in relatives.  </li>
<li style="margin-left: 0px;">Environmental/early‑life exposures (antibiotics, acid suppressants, rural living) linked to disease onset.  </li>
</ul>
</div></details>
<details><summary><strong>1.3 Clinical Burden  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">High health‑care utilization: endoscopies, biopsies, emergency visits for impactions.  </li>
<li style="margin-left: 0px;">Significant impact on quality of life, nutrition, growth (children).  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>2. Pathophysiology &amp; Disease Mechanisms  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Type 2 immune response</strong> triggered by food allergens → epithelial barrier breach.  </li>
<li style="margin-left: 0px;">Eosinophils are key effectors but not sole drivers; mast cells, Th2 cells, iNKT, basophils also infiltrate.  </li>
</ul>
<details><summary><strong>2.1 Cellular &amp; Molecular Landscape  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">↑ eotaxin‑3 (CCL26) expression → eosinophil recruitment (PPI may down‑regulate).  </li>
<li style="margin-left: 0px;">IL‑4/IL‑13 signaling via IL‑4Rα central; targeted by dupilumab.  </li>
<li style="margin-left: 0px;">STAT6, TGF‑β1, and periostin pathways contribute to fibrostenosis.  </li>
</ul>
</div></details>
<details><summary><strong>2.2 Tissue Remodeling &amp; Fibrostenosis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Chronic inflammation → basal zone hyperplasia, dilated intercellular spaces, lamina propria fibrosis.  </li>
<li style="margin-left: 0px;">Esophageal wall thickening (submucosa + muscularis) leads to strictures/narrow caliber.  </li>
<li style="margin-left: 0px;">Phenotypic shift: inflammatory → fibrostenotic phenotype in majority without treatment.  </li>
</ul>
</div></details>
<details><summary><strong>2.3 Biomarkers &amp; Histologic Scoring  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Peak eosinophil count</strong> ≥15 eos/hpf diagnostic threshold (≈60 eos/mm²).  </li>
<li style="margin-left: 0px;"><strong>EoE Histologic Scoring System (EoEHSS):</strong> grades 8 features (eosinophils, basal hyperplasia, etc.).  </li>
<li style="margin-left: 0px;">Emerging markers: mast cell density, IgG4 levels, epigenetic methylation signatures (research stage).  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3. Diagnosis of Eosinophilic Esophagitis  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>3.1 Core Diagnostic Criteria (≥ Low‑quality evidence; Strong recommendation)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Symptoms of esophageal dysfunction</strong> (age‑specific).  </li>
<li style="margin-left: 0px;"><strong>Peak eosinophil count ≥15 eos/hpf</strong> on esophageal biopsy.  </li>
<li style="margin-left: 0px;"><strong>Exclusion of other causes</strong> of esophageal eosinophilia (GERD, infections, etc.).  </li>
</ul>
</div></details>
<details><summary><strong>3.2 Symptom Assessment (Adults &amp; Adolescents)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Dysphagia &amp; food impaction most common; heartburn/chest pain may coexist.  </li>
<li style="margin-left: 0px;">“IMPACT” behaviors to elicit: Imbibe fluids, Modify foods, Prolong meals, Avoid hard textures, Chew excessively, Turn away pills.  </li>
</ul>
</div></details>
<details><summary><strong>3.3 Pediatric Symptom Nuances  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Infants/young children: poor growth, feeding intolerance, prolonged meal times, vomiting/regurgitation.  </li>
<li style="margin-left: 0px;">School‑age: abdominal pain, reflux‑like symptoms; may mask dysphagia.  </li>
</ul>
</div></details>
<details><summary><strong>3.4 Endoscopic Evaluation (Strong recommendation)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Perform <strong>systematic endoscopy</strong> with EREFS scoring at every procedure.  </li>
<li style="margin-left: 0px;">Typical findings (≥1 of 5): edema, rings, exudates, furrows, strictures → not pathognomonic but raise suspicion.  </li>
</ul>
<details><summary><strong>3.4.1 EREFS Details  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Scoring range 0‑9; each feature graded 0‑3 (worst area).  </li>
<li style="margin-left: 0px;">Validated for diagnosis &amp; monitoring; correlates with treatment response.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3.5 Biopsy Protocol (Strong recommendation)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Obtain <strong>≥6 biopsies</strong> from ≥2 esophageal levels (proximal + distal).  </li>
<li style="margin-left: 0px;">Target areas with endoscopic abnormalities when possible.  </li>
<li style="margin-left: 0px;">Diagnostic sensitivity approaches ≈100% with ≥6 biopsies; patchy eosinophilia otherwise missed.  </li>
</ul>
</div></details>
<details><summary><strong>3.6 Histologic Quantification (Strong recommendation)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Quantify peak eos/hpf</strong> on every biopsy set; report absolute count &amp; density (eos/mm²).  </li>
<li style="margin-left: 0px;">Recognize variability by microscope field size; consider reporting density for consistency.  </li>
</ul>
</div></details>
<details><summary><strong>3.7 Ancillary Diagnostic Tools (Key concepts)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Clinical prediction models (e.g., IMPACT, I‑SEE) aid pre‑biopsy risk stratification.  </li>
<li style="margin-left: 0px;">Endoscopic ultrasonography &amp; FLIP can assess submucosal thickening &amp; distensibility but not routine.  </li>
</ul>
</div></details>
<details><summary><strong>3.8 Exclusion of Mimickers  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Rule out GERD, eosinophilic gastroenteritis, infections, drug reactions, hypereosinophilic syndromes.  </li>
<li style="margin-left: 0px;">PPI trial no longer required; PPIs now a treatment option rather than diagnostic filter.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Initial Management Framework (Introductory Overview)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Goal: control <strong>inflammatory</strong> and <strong>fibrostenotic</strong> components simultaneously.  </li>
<li style="margin-left: 0px;">First‑line anti‑inflammatory choice based on shared decision‑making (patient preference, comorbidities, cost).  </li>
</ul>
<details><summary><strong>4.1 Therapeutic Options (Evidence grades)  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Modality</th>
<th>Evidence Quality</th>
<th>Recommendation Strength</th>
</tr></thead>
<tbody>
<tr>
<td><strong>Proton Pump Inhibitors</strong></td>
<td>Low</td>
<td>Conditional suggestion (“high‑dose” PPI)</td>
</tr>
<tr>
<td><strong>Swallowed Topical Steroids</strong> (budesonide, fluticasone)</td>
<td>Moderate</td>
<td>Strong recommendation</td>
</tr>
<tr>
<td><strong>Empiric Food Elimination Diets</strong> (1‑6 FED)</td>
<td>Low</td>
<td>Conditional suggestion</td>
</tr>
<tr>
<td><strong>Dupilumab</strong> (≥12 y)</td>
<td>Moderate</td>
<td>Conditional suggestion</td>
</tr>
<tr>
<td><strong>Esophageal Dilation</strong> (strictures)</td>
<td>Low</td>
<td>Conditional suggestion</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Feeding therapy</strong> adjunct for children with feeding dysfunction or aversion.  </li>
</ul>
</div></details>
<details><summary><strong>4.2 Monitoring &amp; Follow‑up (Strong recommendation)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Assess <strong>symptoms, endoscopy (EREFS), and histology</strong> at 8‑12 weeks after initiating any new therapy.  </li>
<li style="margin-left: 0px;">Use combined outcome (“deep remission”) when feasible: symptom resolution + EREFS ≤ 2 + eos &lt; 15/hpf.  </li>
</ul>
<p><em>The above sections constitute the first portion of the guideline, covering epidemiology, pathophysiology, and detailed diagnostic criteria with initial management considerations.</em></p>
</div></details>
</div></details>
<details><summary><strong>5. Pharmacologic Therapy  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>5.1 Proton Pump Inhibitors (PPIs)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Indication:</strong> All ages, as anti‑inflammatory or adjunct.  </li>
<li style="margin-left: 0px;"><strong>Dosing:</strong> Adults → double standard reflux dose (e.g., omeprazole 40 mg BID).  </li>
<li style="margin-left: 20px;">Children → 2 mg/kg/day (or 1 mg/kg BID).  </li>
<li style="margin-left: 0px;"><strong>Mechanisms of Action</strong>  </li>
<li style="margin-left: 20px;">↓ eotaxin‑3 expression → eosinophil recruitment.  </li>
<li style="margin-left: 20px;">Improves epithelial barrier integrity.  </li>
<li style="margin-left: 20px;">Modulates transcriptional homeostasis in esophageal epithelium.  </li>
<li style="margin-left: 0px;"><strong>Efficacy Data</strong>  </li>
<li style="margin-left: 20px;">Small RCTs: esomeprazole ↓ eos/hpf from ≈46 → 22 (eosinophil count).  </li>
<li style="margin-left: 20px;">Meta‑analysis (33 studies): clinical response ~61 %; histologic remission ~51 %.  </li>
<li style="margin-left: 20px;">Twice‑daily dosing superior to once‑daily (55.9 % vs 49.7 %).  </li>
<li style="margin-left: 0px;"><strong>Predictors of Response</strong>  </li>
<li style="margin-left: 20px;">Younger age, lower BMI, higher baseline eosinophils → nonresponse.  </li>
<li style="margin-left: 20px;">CYP2C19 rapid metabolism may reduce efficacy; dose escalation can overcome.  </li>
<li style="margin-left: 20px;">Presence of allergic rhinitis, STAT6 polymorphisms associated with poorer response.  </li>
<li style="margin-left: 0px;"><strong>Safety Profile</strong>  </li>
<li style="margin-left: 20px;">Long‑term data: no increased risk for CKD, dementia, pneumonia, fractures, COPD, diabetes.  </li>
<li style="margin-left: 20px;">↑ risk of <em>Clostridioides difficile</em> infection only notable adverse event.  </li>
</ul>
</div></details>
<details><summary><strong>5.2 Swallowed Topical Steroids (STCs)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Formulations</strong>  </li>
<li style="margin-left: 20px;">Budesonide oral suspension (BOS) 2 mg BID (FDA‑approved 2024).  </li>
<li style="margin-left: 20px;">Budesonide orodispersible tablet (BOT) 1 mg BID (EMA‑approved 2018).  </li>
<li style="margin-left: 20px;">Fluticasone propionate inhaler powder swallowed from MDI (off‑label).  </li>
<li style="margin-left: 0px;"><strong>Administration Recommendations</strong>  </li>
<li style="margin-left: 20px;">Take after meals; avoid food/drink for 30–60 min → maximize esophageal dwell time.  </li>
<li style="margin-left: 20px;">For children, use slurry or viscous preparation rather than inhaler device.  </li>
<li style="margin-left: 0px;"><strong>Efficacy</strong>  </li>
<li style="margin-left: 20px;">Histologic remission (≤15 eos/hpf) 62‑95 % across phase 3 trials.  </li>
<li style="margin-left: 20px;">Symptom improvement variable; PROs often limited by placebo effect.  </li>
<li style="margin-left: 20px;">Meta‑analysis: overall histologic response ~65‑70 %.  </li>
<li style="margin-left: 0px;"><strong>Comparative Studies</strong>  </li>
<li style="margin-left: 20px;">RCT (OVB vs fluticasone MDI): histologic remission 71 % vs 64 % (no significant difference).  </li>
<li style="margin-left: 20px;">No head‑to‑head trials of BOS vs BOT; both achieve high remission rates.  </li>
<li style="margin-left: 0px;"><strong>Safety &amp; Adverse Effects</strong>  </li>
<li style="margin-left: 20px;">Oral/esophageal candidiasis: BOS 3.8 %; BOT 23.7 % (often asymptomatic).  </li>
<li style="margin-left: 40px;">Management: intermittent topical antifungals, dose reduction, or temporary cessation.  </li>
<li style="margin-left: 20px;">Adrenal insufficiency rare (&lt;5 % in induction trials); consider monitoring with long‑term high‑dose use.  </li>
<li style="margin-left: 0px;"><strong>Predictors of Nonresponse</strong>  </li>
<li style="margin-left: 20px;">Extremely narrow esophageal caliber, prior dilation, TGF‑β1 SNPs, methylation signatures.  </li>
</ul>
</div></details>
<details><summary><strong>5.3 Biologic Therapy – Dupilumab  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Target Population</strong>  </li>
<li style="margin-left: 20px;">Age ≥12 y (adult/adolescent) or 1–11 y (pediatric) nonresponsive to PPIs.  </li>
<li style="margin-left: 0px;"><strong>Mechanism</strong>: IL‑4Rα blockade → inhibits IL‑4 &amp; IL‑13 signaling (type 2 pathway).  </li>
<li style="margin-left: 0px;"><strong>Dosing</strong>  </li>
<li style="margin-left: 20px;">≥40 kg: 300 mg SC weekly (adults).  </li>
<li style="margin-left: 20px;">15–30 kg: 200 mg SC every other week (peds).  </li>
<li style="margin-left: 20px;">30–40 kg: 300 mg SC every other week (peds).  </li>
<li style="margin-left: 0px;"><strong>Clinical Trial Outcomes</strong>  </li>
<li style="margin-left: 20px;">Histologic remission: 60 % dupilumab vs 5 % placebo (Phase 3, 24 wks).  </li>
<li style="margin-left: 20px;">Dysphagia score ↓21.9 points vs 9.6 placebo; significant improvement.  </li>
<li style="margin-left: 20px;">Endoscopic severity (EREFS) and histologic scores improved across dosing regimens.  </li>
<li style="margin-left: 0px;"><strong>Safety</strong>  </li>
<li style="margin-left: 20px;">Injection‑site reactions most common; rare arthralgias.  </li>
<li style="margin-left: 20px;">No increase in infections; no TB, HIV, hepatitis screening required.  </li>
<li style="margin-left: 0px;"><strong>Positioning in Algorithm</strong>  </li>
<li style="margin-left: 20px;">Consider early if comorbid atopic disease meets dupilumab indication (asthma, AD, CRSwNP).  </li>
</ul>
</div></details>
<details><summary><strong>5.4 Other Biologics &amp; Small Molecules (Conditional Recommendations)  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Agent</th>
<th>Target</th>
<th>Evidence Quality</th>
<th>Recommendation</th>
</tr></thead>
<tbody>
<tr>
<td>Cendakimab (anti‑IL‑13)</td>
<td>IL‑13</td>
<td>Low/Phase 2 positive</td>
<td>No recommendation (experimental).</td>
</tr>
<tr>
<td>Benralizumab, Lirentelimab (anti‑IL‑5Rα, anti‑Siglec‑8)</td>
<td>Eosinophil depletion</td>
<td>Low/Phase 2 histologic response ↑; symptom benefit modest</td>
<td>Not recommended currently.</td>
</tr>
<tr>
<td>Omalizumab (anti‑IgE)</td>
<td>IgE</td>
<td>Low/No efficacy in RCTs</td>
<td>Suggest against use.</td>
</tr>
<tr>
<td>Cromolyn, Montelukast (mast‑cell stabilizer, leukotriene antagonist)</td>
<td>Various inflammatory mediators</td>
<td>Very low/limited trials</td>
<td>Suggest against use.</td>
</tr>
<tr>
<td>PCAB (vonoprazan)</td>
<td>Potent acid suppression</td>
<td>Limited data; similar efficacy to PPIs</td>
<td>Not yet recommended.</td>
</tr>
</tbody>
</table>
</div></details>
</div></details>
<details><summary><strong>6. Dietary Elimination Strategies  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>6.1 Rationale &amp; Mechanistic Basis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Food antigens drive type 2 inflammation in &gt;90 % of patients.  </li>
<li style="margin-left: 0px;">Removal → ↓ eosinophilic infiltration, symptom relief, mucosal healing.  </li>
</ul>
</div></details>
<details><summary><strong>6.2 Empiric Elimination Diets (FED)  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Diet</th>
<th>Foods Excluded</th>
<th>Efficacy (Histologic remission)</th>
</tr></thead>
<tbody>
<tr>
<td><strong>1‑Food Elimination (1FED)</strong></td>
<td>Dairy only</td>
<td>35‑45 %</td>
</tr>
<tr>
<td><strong>2‑Food Elimination (2FED)</strong></td>
<td>Dairy + wheat</td>
<td>40‑45 %</td>
</tr>
<tr>
<td><strong>4‑Food Elimination (4FED)</strong></td>
<td>Dairy, wheat, egg, soy</td>
<td>40‑50 %</td>
</tr>
<tr>
<td><strong>6‑Food Elimination (6FED)</strong></td>
<td>Dairy, wheat, egg, soy, nuts/peanut, fish/seafood</td>
<td>40‑70 %</td>
</tr>
<tr>
<td><strong>Elemental Formula</strong></td>
<td>Amino‑acid based hypoallergenic formula</td>
<td>~90 % (if adherent)</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Step‑up approach:</strong> Start with least restrictive (1FED/2FED); progress to 4FED/6FED if no response.  </li>
<li style="margin-left: 0px;"><strong>Reintroduction Protocol</strong>  </li>
<li style="margin-left: 20px;">Add back one food/group every 6–8 weeks.  </li>
<li style="margin-left: 20px;">Perform endoscopy + biopsy after each reintroduction to assess eos/hpf.  </li>
<li style="margin-left: 20px;">“Washout” period (2‑6 wks) required after contamination before repeat scope.  </li>
</ul>
</div></details>
<details><summary><strong>6.3 Practical Implementation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Dietitian involvement</strong> mandatory for nutritional adequacy, label reading, meal planning.  </li>
<li style="margin-left: 0px;"><strong>Feeding therapist</strong> referral if avoidant/restrictive food intake disorder suspected.  </li>
<li style="margin-left: 0px;"><strong>Adherence challenges:</strong> Palatability (especially elemental), cost, multiple endoscopies.  </li>
<li style="margin-left: 0px;"><strong>“Diet holidays”</strong> may be employed during vacations or social events; resume medical therapy concurrently.  </li>
</ul>
</div></details>
<details><summary><strong>6.4 Allergy‑Testing–Guided Diets (Not Recommended)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Skin prick, patch, serum IgE/IgG4 tests have low sensitivity/specificity for identifying triggers.  </li>
<li style="margin-left: 0px;">Meta‑analyses: empiric FED superior to test‑guided diets.  </li>
<li style="margin-left: 0px;">Use allergy testing only for <strong>non‑EoE atopic comorbidities</strong> or when considering oral immunotherapy.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>7. Esophageal Dilation  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>7.1 Indications  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Symptomatic dysphagia due to strictures or narrow caliber esophagus confirmed endoscopically or radiographically.  </li>
<li style="margin-left: 0px;">Adjunctive to anti‑inflammatory therapy (does not treat underlying inflammation).  </li>
</ul>
</div></details>
<details><summary><strong>7.2 Technique &amp; Protocol (Consensus Recommendations)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Goal diameter:</strong> ≥16 mm in adults/adolescents; individualized based on baseline lumen.  </li>
<li style="margin-left: 0px;"><strong>Approach:</strong> “Start low, go slow” – begin with dilator size slightly smaller than target, incrementally increase until mucosal disruption (“dilation effect”) observed.  </li>
<li style="margin-left: 0px;"><strong>Methods:</strong> Bougie (Savary‑Gilliard) or balloon dilation acceptable; choice per endoscopist preference and stricture characteristics.  </li>
</ul>
</div></details>
<details><summary><strong>7.3 Outcomes &amp; Safety  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Clinical improvement in ≈95 % of cases.  </li>
<li style="margin-left: 0px;">Perforation rate ~0.5 %; hospitalization &lt;1 %.  </li>
<li style="margin-left: 0px;">Dilation reduces need for subsequent procedures when inflammation controlled (histologic remission).  </li>
</ul>
</div></details>
<details><summary><strong>7.4 Monitoring Post‑Dilation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Repeat endoscopy if dysphagia persists or recurs.  </li>
<li style="margin-left: 0px;">Continue anti‑inflammatory therapy to prevent re‑narrowing.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8. Maintenance Therapy &amp; Long‑Term Monitoring  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>8.1 Rationale for Maintenance  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">EoE is chronic; cessation of treatment → near universal relapse (clinical, histologic, endoscopic).  </li>
<li style="margin-left: 0px;">Ongoing inflammation promotes fibrostenosis; maintenance mitigates progression.  </li>
</ul>
</div></details>
<details><summary><strong>8.2 Maintenance Strategies  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>8.2.1 Pharmacologic Maintenance  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Topical Steroids</strong>  </li>
<li style="margin-left: 20px;">Continue induction dose or taper to lowest effective dose confirmed by repeat endoscopy/biopsy.  </li>
<li style="margin-left: 20px;">Randomized withdrawal trials: budesonide 0.25 mg BID maintains remission in ≈36 % vs 0 % placebo at 50 weeks.  </li>
<li style="margin-left: 0px;"><strong>PPIs</strong>  </li>
<li style="margin-left: 20px;">“High‑dose” regimen (double reflux dose) effective long‑term in 70‑85 % of patients (1‑3 y follow‑up).  </li>
<li style="margin-left: 0px;"><strong>Dupilumab</strong>  </li>
<li style="margin-left: 20px;">Sustained histologic &amp; symptom remission up to 52 weeks; real‑world data show similar durability.  </li>
</ul>
</div></details>
<details><summary><strong>8.2.2 Dietary Maintenance  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Continue successful elimination diet indefinitely or until trigger identified and permanently excluded.  </li>
<li style="margin-left: 0px;">For patients achieving remission after reintroduction, <strong>single‑food avoidance</strong> of identified triggers may suffice.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8.3 Monitoring Schedule (Strong recommendation)  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Timepoint</th>
<th>Assessment Components</th>
</tr></thead>
<tbody>
<tr>
<td>Baseline (pre‑treatment)</td>
<td>Symptoms, EREFS, peak eos/hpf, I‑SEE severity index.</td>
</tr>
<tr>
<td>8–12 weeks post‑initiation</td>
<td>Repeat endoscopy + biopsies; symptom PROs; adjust therapy as needed.</td>
</tr>
<tr>
<td>Every 6–12 months (stable disease)</td>
<td>Clinical review, consider surveillance endoscopy if dose changes or symptoms recur.</td>
</tr>
<tr>
<td>After dose reduction or treatment change</td>
<td>Endoscopy within 8–12 weeks to confirm continued remission.</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Symptom monitoring</strong>: Use validated PROs (e.g., Dysphagia Symptom Questionnaire, adult EoE‑QoL).  </li>
<li style="margin-left: 0px;"><strong>Endoscopic scoring</strong>: Aim for EREFS ≤ 2; complete normalization (EREFS 0) ideal but not required.  </li>
<li style="margin-left: 0px;"><strong>Histologic target</strong>: &lt;15 eos/hpf (≈60 eos/mm²); consider stricter cutoffs (&lt;5 eos/hpf) in research settings.  </li>
</ul>
</div></details>
<details><summary><strong>8.4 Non‑Invasive Monitoring Options (Emerging)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Transnasal unsedated endoscopy</strong> – feasible in children, reduces anesthesia exposure.  </li>
<li style="margin-left: 0px;"><strong>Cytosponge</strong> – sensitivity 75 %, specificity 86 % for active disease; useful for diet reintroduction monitoring.  </li>
<li style="margin-left: 0px;"><strong>Esophageal String Test</strong> – measures eotaxin‑3 &amp; major basic protein; AUC 0.83 for active vs inactive disease.  </li>
<li style="margin-left: 0px;"><strong>Mucosal impedance &amp; EndoFLIP</strong> – correlate with eosinophilia and distensibility; currently limited to specialized centers.  </li>
</ul>
</div></details>
<details><summary><strong>8.5 Monitoring in Special Populations  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>8.5.1 Pediatric Patients  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Growth (height, weight, BMI) tracked alongside disease activity.  </li>
<li style="margin-left: 0px;">Feeding therapy essential for children with aversive eating behaviors or ARFID.  </li>
<li style="margin-left: 0px;">Endoscopic surveillance performed under sedation; consider transnasal approach when feasible.  </li>
</ul>
</div></details>
<details><summary><strong>8.5.2 Adults with Fibrostenotic Phenotype  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Baseline esophagram or FLIP to assess lumen diameter before dilation.  </li>
<li style="margin-left: 0px;">More frequent endoscopic assessment (every 6‑9 months) due to higher stricture risk.  </li>
</ul>
<p><em>The above sections complete Part 2 of the guideline, detailing pharmacologic and dietary therapies, dilation procedures, maintenance strategies, and comprehensive monitoring protocols.</em></p>
</div></details>
</div></details>
</div></details>
<details><summary><strong>9. Pediatric‑Specific Considerations  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>9.1 Diagnostic Nuances in Children  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Symptom Spectrum</strong> varies by age:  </li>
<li style="margin-left: 20px;">Infants → poor growth, feeding intolerance, prolonged meals.  </li>
<li style="margin-left: 20px;">Toddlers/Preschool → vomiting, regurgitation, food refusal.  </li>
<li style="margin-left: 20px;">School‑age → abdominal pain, dysphagia, heartburn.  </li>
<li style="margin-left: 0px;"><strong>IMPACT Behaviors</strong> (Table 4) essential to uncover concealed dysphagia; children may mask symptoms via avoidance.  </li>
</ul>
<details><summary><strong>9.1.1 Endoscopic Evaluation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Perform under general anesthesia or unsedated transnasal scope (preferred for repeated monitoring).  </li>
<li style="margin-left: 0px;">Obtain ≥6 biopsies from proximal &amp; distal esophagus; targeting visual abnormalities when present.  </li>
</ul>
</div></details>
<details><summary><strong>9.1.2 Imaging Adjuncts  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Esophagram</strong> recommended in dysphagia to detect strictures not apparent endoscopically (detected in 55 % of cases with normal endoscopy).  </li>
<li style="margin-left: 0px;"><strong>EndoFLIP</strong> may be used in specialized centers for assessing distensibility, especially when radiation avoidance is desired.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>9.2 Growth, Development &amp; Nutrition Goals  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Primary endpoints: <strong>linear growth</strong>, <strong>weight gain</strong>, and <strong>BMI trajectory</strong> alongside symptom control.  </li>
<li style="margin-left: 0px;"><strong>Dietitian involvement</strong> mandatory for all children on elimination diets to prevent macro‑/micronutrient deficiencies.  </li>
<li style="margin-left: 0px;">Monitor serum ferritin, pre‑albumin, vitamin D, PTH periodically; supplement as needed.  </li>
</ul>
</div></details>
<details><summary><strong>9.3 Feeding Therapy &amp; Behavioral Interventions  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Up to 16.5 % of pediatric EoE patients have feeding disorders; 93.9 % exhibit maladaptive behaviors (e.g., prolonged meals, excessive chewing).  </li>
<li style="margin-left: 0px;"><strong>Multidisciplinary program</strong>: gastroenterology + dietetics + speech‑language pathology + psychology.  </li>
<li style="margin-left: 0px;">Positive reinforcement techniques improve oral intake; avoid negative stimuli (pain, dysphagia) during therapy sessions.  </li>
</ul>
</div></details>
<details><summary><strong>9.4 Pharmacologic Therapy in Children  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>9.4.1 Swallowed Topical Steroids  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Budesonide oral viscous slurry</strong> (1–2 mg/day) or <strong>fluticasone MDI</strong> (110‑880 µg/day) effective; dosing weight‑adjusted.  </li>
<li style="margin-left: 0px;">Monitor for oral candidiasis; treat with topical antifungals if symptomatic.  </li>
</ul>
</div></details>
<details><summary><strong>9.4.2 Proton Pump Inhibitors  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">High‑dose regimen (double standard dose) used when steroids contraindicated or as adjunct.  </li>
</ul>
</div></details>
<details><summary><strong>9.4.3 Dupilumab (Ages 1–11)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">FDA‑approved for ≥15 kg; dosing every other week based on weight bands.  </li>
<li style="margin-left: 0px;">Demonstrated histologic remission ≈68 % (high dose) and growth improvement over 52 weeks.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>9.5 Dietary Management in Children  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>9.5.1 Empiric Elimination Diets  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>1‑FED (dairy)</strong> often first line due to high prevalence of milk trigger; remission rates ≈35‑45 %.  </li>
<li style="margin-left: 0px;"><strong>2‑FED (dairy + wheat)</strong> modestly higher response; consider if 1‑FED fails.  </li>
<li style="margin-left: 0px;"><strong>4‑FED / 6‑FED</strong> reserved for refractory disease or when multiple triggers suspected.  </li>
</ul>
</div></details>
<details><summary><strong>9.5.2 Elemental Formula  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Reserved for infants, severe refractory cases, or when oral intake impossible.  </li>
<li style="margin-left: 0px;">Requires feeding tube in many patients; high cost and adherence challenges.  </li>
</ul>
</div></details>
<details><summary><strong>9.5.3 Reintroduction Protocol  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">After 6‑8 weeks of diet, reintroduce foods sequentially (single food per interval).  </li>
<li style="margin-left: 0px;">Perform endoscopy after each reintroduction to assess eos/hpf; if remission persists, the food is deemed non‑triggering.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>9.6 Monitoring &amp; Follow‑up in Pediatrics  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Interval</th>
<th>Assessments</th>
</tr></thead>
<tbody>
<tr>
<td>Baseline</td>
<td>Height/weight/BMI percentiles, symptom questionnaire, EREFS, biopsies.</td>
</tr>
<tr>
<td>8–12 weeks post‑therapy start</td>
<td>Repeat endoscopy + biopsies; growth parameters; diet adherence check.</td>
</tr>
<tr>
<td>Every 6 months (stable)</td>
<td>Clinical review, growth tracking; consider non‑invasive monitoring (transnasal scope).</td>
</tr>
<tr>
<td>After dose reduction or therapy change</td>
<td>Endoscopy within 8–12 weeks to confirm continued remission.</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Adrenal insufficiency</strong> rare but monitor cortisol if high‑dose steroids &gt;6 months.  </li>
<li style="margin-left: 0px;"><strong>Vaccination considerations:</strong> live vaccines deferred during systemic steroid bursts; otherwise routine schedule maintained.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>10. Monitoring of Treatment Response &amp; Outcome Metrics  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>10.1 Composite “Deep Remission” Concept  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Definition:</strong> Symptom resolution + EREFS ≤ 2 + peak eos &lt; 15/hpf (≈60 eos/mm²).  </li>
<li style="margin-left: 0px;">Achievable in ~9 % of patients; associated with lower relapse rates but requires intensive therapy.  </li>
</ul>
</div></details>
<details><summary><strong>10.2 Symptom Assessment Tools  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Tool</th>
<th>Population</th>
<th>Domains</th>
</tr></thead>
<tbody>
<tr>
<td>Dysphagia Symptom Questionnaire (DSQ)</td>
<td>Adults/Adolescents</td>
<td>Frequency &amp; severity of dysphagia, food impaction.</td>
</tr>
<tr>
<td>Adult EoE‑QoL</td>
<td>Adults</td>
<td>Health‑related quality of life across 4 domains.</td>
</tr>
<tr>
<td>Pediatric Quality of Life Inventory – EoE module</td>
<td>Children ≥5 y</td>
<td>Symptom burden, emotional impact, social functioning.</td>
</tr>
<tr>
<td>IMPACT behavior checklist</td>
<td>All ages</td>
<td>Specific dysphagia‑related coping behaviors.</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">PROs should be collected at each visit; correlate modestly with endoscopic/histologic findings (r≈0.3‑0.4).  </li>
</ul>
</div></details>
<details><summary><strong>10.3 Endoscopic Scoring – EREFS  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Scoring components:</strong> Edema, Rings, Exudates, Furrows, Strictures (0‑3 each).  </li>
<li style="margin-left: 0px;"><strong>Interpretation:</strong> Total 0–9; response threshold often set at ≤2 or ≥2‑point reduction from baseline.  </li>
</ul>
</div></details>
<details><summary><strong>10.4 Histologic Evaluation  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Parameter</th>
<th>Threshold for Remission</th>
</tr></thead>
<tbody>
<tr>
<td>Peak eos/hpf</td>
<td>&lt;15 (≈60 eos/mm²)</td>
</tr>
<tr>
<td>EoEHSS total grade</td>
<td>↓ by ≥1 point in ≥50 % of features</td>
</tr>
<tr>
<td>Basal zone hyperplasia, lamina propria fibrosis</td>
<td>Absent or minimal (optional for deep remission).</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Report absolute eos count and density; note any additional histologic features (e.g., basal hyperplasia) that may indicate ongoing activity despite low eos.  </li>
</ul>
</div></details>
<details><summary><strong>10.5 Non‑Invasive &amp; Minimally Invasive Biomarkers  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Modality</th>
<th>Sensitivity / Specificity*</th>
<th>Clinical Utility</th>
</tr></thead>
<tbody>
<tr>
<td>Cytosponge</td>
<td>75 % / 86 %</td>
<td>Detect active disease; useful for diet reintroduction monitoring.</td>
</tr>
<tr>
<td>Esophageal String Test (eotaxin‑3, MBP)</td>
<td>AUC 0.83</td>
<td>Distinguish active vs inactive disease; requires 1‑hour dwell time.</td>
</tr>
<tr>
<td>Mucosal Impedance</td>
<td>Variable (higher in remission)</td>
<td>Correlates with eosinophil density; limited to specialized centers.</td>
</tr>
<tr>
<td>EndoFLIP Distensibility Index</td>
<td>↓ in fibrostenosis</td>
<td>Guides dilation decisions; not a direct inflammation marker.</td>
</tr>
</tbody>
</table>
<p>*Values derived from pooled studies; performance may vary by cohort.</p>
</div></details>
<details><summary><strong>10.6 Timing of Monitoring  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Initial response:</strong> endoscopy + biopsy at 8‑12 weeks after therapy initiation (PPIs, STCs, FED).  </li>
<li style="margin-left: 0px;"><strong>Biologic agents (dupilumab):</strong> consider 12‑24 weeks for first assessment due to longer onset.  </li>
<li style="margin-left: 0px;"><strong>Maintenance phase:</strong> repeat endoscopy every 12‑24 months if stable; sooner if symptoms recur or dose changes occur.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>11. Algorithmic Treatment Pathway (Figure 3 Summary)  </strong></summary><div style="padding-left: 20px;">
<p>1. <strong>Confirm Diagnosis</strong> → Symptoms + ≥15 eos/hpf + exclusion of other causes.</p>
<p>2. <strong>Assess Phenotype</strong>: Inflammatory vs fibrostenotic (stricture, narrow caliber).</p>
<p>3. <strong>Shared Decision‑Making</strong> → Choose anti‑inflammatory modality:</p>
<ul style="list-style-type: disc;">
<li style="margin-left: 30px;"><strong>PPIs</strong> (high‑dose) OR  </li>
<li style="margin-left: 30px;"><strong>Swallowed Topical Steroid</strong> (BOS/BOT or fluticasone) OR  </li>
<li style="margin-left: 30px;"><strong>Empiric Elimination Diet</strong> (1FED→2FED→4FED→6FED).  </li>
</ul>
<p>4. <strong>Concurrent Management of Fibrostenosis</strong>:</p>
<ul style="list-style-type: disc;">
<li style="margin-left: 30px;">If stricture present → endoscopic dilation (start low, go slow).  </li>
</ul>
<p>5. <strong>8‑12 Week Assessment</strong> → Symptoms, EREFS, eos/hpf.</p>
<ul style="list-style-type: disc;">
<li style="margin-left: 30px;"><strong>Responder:</strong> Continue therapy; consider dose taper if stable.  </li>
<li style="margin-left: 30px;"><strong>Partial/Non‑Responder:</strong> Switch modality (e.g., STC ↔ PPI ↔ diet) or add dupilumab.  </li>
</ul>
<p>6. <strong>Maintenance Therapy</strong> → Ongoing anti‑inflammatory agent at lowest effective dose + periodic monitoring.</p>
</div></details>
<details><summary><strong>12. Future Directions &amp; Knowledge Gaps  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Gap</th>
<th>Research Priority</th>
</tr></thead>
<tbody>
<tr>
<td>Comparative effectiveness of first‑line therapies (PPI vs STC vs diet)</td>
<td>Head‑to‑head RCTs with standardized outcomes.</td>
</tr>
<tr>
<td>Predictors of treatment response (genetic, epigenetic, microbiome)</td>
<td>Development of personalized algorithms incorporating biomarkers.</td>
</tr>
<tr>
<td>Phenotype/endotype classification (inflammatory vs fibrostenotic)</td>
<td>Validation of I‑SEE and FLIP metrics for risk stratification.</td>
</tr>
<tr>
<td>Non‑invasive monitoring tools</td>
<td>Large‑scale validation of Cytosponge, string test, mucosal impedance.</td>
</tr>
<tr>
<td>Long‑term safety of biologics in pediatric population</td>
<td>Extended follow‑up registries for growth, immunogenicity, infection risk.</td>
</tr>
<tr>
<td>Cost‑effectiveness analyses across treatment modalities</td>
<td>Incorporate drug costs, diet adherence resources, endoscopy frequency.</td>
</tr>
<tr>
<td>Role of combination therapy (e.g., PPI + STC)</td>
<td>Trials to assess additive benefit vs monotherapy.</td>
</tr>
<tr>
<td>Novel therapeutic targets (TSLP, IL‑15, mast‑cell stabilizers)</td>
<td>Phase 2/3 trials for emerging agents (tezepelumab, barzovolimab).</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Implementation Science:</strong> Need strategies to reduce diagnostic delay, educate primary‑care providers, and standardize biopsy protocols.  </li>
<li style="margin-left: 0px;"><strong>Patient‑Centric Outcomes:</strong> Emphasize quality‑of‑life metrics, feeding behavior interventions, and shared decision‑making frameworks.  </li>
</ul>
<p><em>End of Part 3 – complete extraction and hierarchical organization of the ACG guideline on eosinophilic esophagitis.</em></p>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
